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Abstract
Silica monoliths in affinity microcolumns were tested for the high-throughput analysis of drug–protein interactions. HSA was used as a model protein for this work, while carbamazepine and R-warfarin were used as model analytes. A comparison of HSA silica monoliths of various lengths indicated
columns as short as 1 to 3 mm could be used to provide reproducible estimates of retention factors or
plate heights. Benefits of using smaller columns for this work included the lower retention times and
lower back pressures that could be obtained versus traditional HPLC affinity columns, as well as the
smaller amount of protein that is required for column preparation. One disadvantage of decreasing column length was the lower precision that resulted in retention factor and plate height measurements. A
comparison was also made between microcolumns containing silica particles versus silica monoliths. It
was demonstrated with R-warfarin that supports could be used in HSA microcolumns for the determination of retention factors or plate heights. However, the higher efficiency of the silica monolith made
this the preferred support for work at higher flow rates or when a larger number of plates are needed
during the rapid analysis of drug–protein interactions.
Keywords: affinity chromatography, drug– protein binding, human serum albumin, silica monolith /
Abbreviation: AMC, affinity monolith chromatography

1 Introduction
A monolithic support consists of a continuous bed that
has both large through-pores to permit solvent flow and
smaller side pores for analyte interactions with the stationary phase. These properties tend to give monoliths
better mass transfer properties, higher permeability, and
lower back-pressures than traditional particulate supports for HPLC [1]. Monolithic supports have already
been used in many types of LC [2–5]. These supports
have also recently become of interest for use in affinity
chromatography, a method in which the stationary phase
is a biological-related ligand; the resulting combination of
affinity ligands and monolithic supports is referred to as
affinity monolith chromatography (AMC) [6].
Various support materials have been considered for
use in AMC, including GMA/EDMA co-polymers [7–17],
agarose [18, 19], and cryogels [20, 21], among others. Silica monoliths are another set of supports that have been

explored for use in AMC [22–26]. Silica monoliths are attractive for AMC because they combine the benefits of
monolithic supports with the use of a silica-based support, which makes it possible to adapt many of the immobilization schemes already employed in the creation of affinity columns using silica particles [6, 26, 27]. Previous
applications of silica monoliths in AMC have included
their use in the chiral separations of drugs using immobilized serum proteins [23, 26], the screening of enzyme
inhibitors [28], the high-throughput analysis of enzymes
and proteins [29], and separations based on immobilized
metal-ion affinity chromatography [30].
Another possible application of AMC is in the analysis
of drug–protein interactions. HSA is the most abundant
plasma protein in humans and is known to bind to various drugs and hormones, affecting the transport, distribution, metabolism, and excretion of such substances [31–
33]. There are two major binding sites for drugs on HSA,
which are referred to as Sudlow sites I and II [31]. Two
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silica monoliths and those with silica particles. This information will be used to determine the feasibility of using
affinity microcolumns and silica monoliths for the highthroughput analysis of drug–protein interactions and to
identify chromatographic conditions that are suitable for
such work.

2 Experimental
2.1 Reagents

Figure 1. Structures of (a) carbamazepine and (b) warfarin.
The asterisk shows the location of the chiral center in warfarin.

drugs that have well-known binding properties at these
sites are warfarin and carbamazepine (see Figure 1). Warfarin is an anticoagulant drug known to bind to Sudlow
site I [31, 34], while carbamazepine is an anticonvulsant
drug that binds to Sudlow site II [35–37]. The binding of
both of these drugs has previously been examined using traditional HPLC affinity columns in which HSA has
been immobilized to silica particles [34, 36, 38– 40].
HPLC affinity columns have been shown in previous
studies to be useful in the analysis of drug–protein interactions, such as those that occur in blood [41, 42]. The
results obtained when using immobilized HSA in standard HPLC columns give good agreement with data obtained by reference methods using soluble HSA (e.g.,
equilibrium dialysis and ultrafiltration) [39, 41]. Experiments that can be conducted with these columns range
from the measurement of percentage binding and binding affinity to kinetic studies and drug–drug competition studies [39, 40]. The advantages of using HPLC affinity columns for this work include the ability to reuse
the same protein preparation for many experiments,
the good precision and accuracy of this approach, and
the relative speed at which binding studies can be conducted [41, 42].
This study will examine the creation and use of affinity
microcolumns containing silica monoliths for use in the
analysis of drug–protein interactions. HSA will be used
as the model protein and R-warfarin or carbamazepine
will be the drugs employed in this study. Retention factors and plate heights will be measured for these systems,
representing the main parameters used in zonal elution
studies to examine drug–protein binding on traditional
HPLC affinity columns [39–41, 43]. A comparison will
also be made between affinity microcolumns containing

HSA (Cohn fraction V, essentially fatty acid free, ≥96%
pure), carbamazepine (≥98% pure), and R-warfarin (≥97%
pure) were from Sigma (St. Louis, MO, USA). Nucleosil Si-300 silica (300 Å pore size, 7 μm particle size) was
from Macherey Nagel (Düren, Germany). Reagents for
the bicinchoninic acid (BCA) protein assay were from
Pierce (Rockford, IL, USA). All buffers and aqueous solutions were prepared using water from a Nanopure system (Barnstead, Dubuque, IA, USA) and filtered using
Osmonics 0.22 μm nylon filters from Fisher (Pittsburgh,
PA, USA).
2.2 Apparatus
The Chromolith Performance Si column (4.6 mm i.d. × 10
cm) was donated by Merck KGaA (Darmstadt, Germany).
From this column, 1, 3, and 5 mm long pieces were cut
to make shorter silica monolith columns by using a lathe.
Reagents to activate the silica monolith and immobilize
HSA were applied using a Beckman System Gold 118 Solvent Module pump (Fullerton, CA, USA). The silica particle-based columns (3 mm × 2.1 mm i.d.) were packed using an Alltech slurry packer (Deerfield, IL, USA).
The chromatographic system consisted of an isocratic
HPLC PU-2080 Plus pump and a UV-2075 Plus detector
from Jasco (Easton, MD, USA). Injection was carried out
by using a six-port Rheodyne Lab Pro valve (Cotati, CA,
USA) and a 5 μL sample loop. An Alltech water jacket
and a circulating water bath from Fisher were used to
control the temperature in the chromatographic columns.
Chromatographic data were collected and processed using in-house programs written in LabView 5.1 (National
Instruments, Austin, TX, USA).
2.3 Preparation of HSA silica monoliths
Each silica monolith was first converted into a diolbonded form, as described previously [23]. To do this, a
1–5 mm long section of the original silica monolith was
cut and assembled into a column housing made of delrin.
Each of these silica monoliths was first washed with 0.10
M, pH 5.5 sodium acetate buffer for 40 min at 0.5 mL/
min (unless otherwise indicated, the following steps were
conducted at room temperature). Pure 3- glycidoxypropyltrimethoxysilane was passed through the monolith for
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Figure 2. Preparation of a HSA silica
monolith by the Schiff base method.

50 min at 0.2 mL/min, as used previously for longer silica monoliths in reference [23]. After sealing both ends,
the monolith column was placed in a water bath at 97°C
for 5 h. A solution of 0.10 M, pH 5.5 sodium acetate buffer was used to wash the column for 50 min at 0.1 mL/
min and pure 3-glycidoxypropyltrimethoxysilane was
again passed through the column for 50 min at 0.1 mL/
min to ensure maximum diol coverage. The column ends
were sealed and the column was placed in a water bath
at 97°C for 5 h. The column was removed from the water
bath and washed with water for 4 h at 0.2 mL/min. A pH
3.0 solution of dilute sulfuric acid in water was passed
through the column for 50 min at 0.2 mL/min. The column was then again sealed at both ends and placed in a
water bath at 70°C for 3 h. All of the resulting diol silica
monolith columns were washed with water at 0.2 mL/
min for over 5 h. Some of these columns were used for
HSA immobilization while others were used as control
columns in further studies.
HSA was immobilized onto the diol silica monolith
by using the Schiff base method (see Figure 2) [23]. In
this method, a 90% v/v acetic acid solution in water was
passed through each column for 4 h at 0.2 mL/min. A solution of 0.5 g/mL periodic acid in 90% acetic acid in water was then passed through the column in the dark for 7
h at 0.2 mL/min to oxidize the diol groups and form aldehyde groups. The column was washed with water for
8 h at 0.2 mL/min. A 10 mL solution containing 50 mg
HSA and 25 mg sodium cyanoborohydride (a mild reducing agent) in 1.5 M, pH 6.0 potassium phosphate buffer was circulated through each column for 24 h at 0.5 mL/
min. Separate HSA solutions were used in this step and
the next for each column. The sodium cyanoborohydride
was used to reduce the reversible Schiff bases formed between amine groups on HSA and aldehyde groups on the
support, resulting in stable secondary amine linkages (because it is a mild reducing agent, the sodium cyanoborohydride did not reduce the original aldehydes prior to their
reaction with amines). A second fresh 12 mL solution of 60
mg HSA and 30 mg sodium cyanoborohydride in the same
pH 6.0 buffer was circulated through the column for 65 h
at 0.5 mL/min. A 5 mL solution of 0.10 M, pH 8.0 potassium phosphate buffer containing 1 mg/mL sodium bo-

rohydride (a strong reducing agent) was applied to each
column for 1.5 h at 0.05 mL/min using a syringe pump
(Harvard Apparatus, Holliston, MA, USA), with this solution being used to reduce any remaining aldehydes on the
support. The monolith columns were then washed with
0.10 M, pH 8.0 potassium phosphate buffer containing 0.5
M sodium chloride, which was passed through each column for 50 min at 0.2 mL/min, followed by an additional
washing with 0.067 M, pH 7.4 potassium phosphate buffer for 1.5 h at 0.5 mL/min. The resulting HSA silica monoliths were stored in this last buffer at 4°C until use. These
columns were used within a period of three months. Similar but longer silica monoliths have been found to be stable
for at least four months under the storage and experimental conditions used in this study [23].
The protein content in the HSA silica monoliths was
estimated as described in ref. [23] by measuring the retention factor for 5 μL injections of 30 μM carbamazepine
in the presence of pH 7.4, 0.067 M potassium phosphate.
Similar injections were made onto the control columns to
correct for any nonspecific binding of carbamazepine to
the support. It was found that nonspecific binding typically made up 21–33% of the total retention seen on the
HSA silica monoliths. The estimated protein coverage of
these supports was 1.8 (±0.1) μmol HSA/g support [23].
This result corresponded to a protein content in each column of 0.36 (±0.02) μmol HSA/mL.
2.4 Preparation of HSA silica particles
To prepare the particle-based supports, Nucleosil Si300, 7 μm particle size silica was converted into a diolbonded form, as described previously [44]. A particle
size of 7 μm was chosen for this work because it has been
commonly used in the past to prepare immobilized HSA
for use in HPLC affinity columns for drug–protein binding studies [34, 36, 38–40]. HSA was immobilized onto
part of this diol silica by using the Schiff base method
[45], with the remainder of the diol silica being used to
prepare a control support in which no HSA was added
to the silica. In the Schiff base method, 0.5 g of diol silica was combined with 0.5 g periodic acid in 10 mL of a
90% v/v solution of acetic acid in water, with this mix-
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ture then being allowed to react for 2 h with shaking. The
resulting aldehyde- activated silica was then washed six
times with water and three times with 0.10 M, pH 6.0 potassium phosphate buffer.
The aldehyde-activated silica from the previous step
was combined with a 5 mL solution of 0.10 M, pH 6.0 potassium phosphate buffer containing 50 mg HSA and 25
mg sodium cyanoborohydride. This mixture was allowed
to shake on a rotary mixer at 4°C for 6 days. The HSA silica that this reaction produced was washed four times
with 0.10 M, pH 8.0 potassium phosphate buffer and
slowly combined with three portions of 12 mg sodium
borohydride, which were added over the course of 90
min while the mixture was allowed to react at room temperature. This slurry was washed three times with 0.10
M, pH 8.0 potassium phosphate buffer that contained 0.5
M sodium chloride, followed by two additional washings
with 0.067 M, pH 7.4 potassium phosphate buffer. The final HSA silica and corresponding control support were
stored in 0.067 M, pH 7.4 potassium phosphate buffer at
4°C until use.
Small portions of the HSA silica and control support
were washed several more times with water and dried
under vacuum at room temperature. These dried samples were analyzed in triplicate using a BCA protein assay [46], with HSA being employed as the standard and
the control support being used as the blank. The final protein content of the HSA silica was found to be 0.76 (±0.05)
μmol HSA/g support, which corresponded to a protein
content of 0.34 (±0.02) μmol HSA/mL. The remaining
portions of the original HSA silica and control support
were downward slurry packed at 4000 psi (28 MPa) for 40
min into stainless steel columns using 0.067 M, pH 7.4 potassium phosphate buffer as the packing solution. These
columns were stored in pH 7.4, 0.067 M potassium phosphate buffer at 4°C until use. These columns were used
within a period of 3 months and are typically stable for
up to one year under the storage and experimental conditions used in this study [47].
2.5 Chromatographic studies
The mobile phase used throughout these studies was
pH 7.4, 0.067 M potassium phosphate buffer. The column temperature was maintained at 37.0 (±0.1)°C during all experiments. A 5 μL injection volume was used
for all samples, with each sample being injected in triplicate under all of the tested chromatographic conditions. All samples were prepared in 0.067 M, pH 7.4 potassium phosphate buffer and stored at 4°C when not in
use. Solutions of R-warfarin were stored at 4°C for up to
one week, and solutions of carbamazepine were stored at
4°C for several weeks; both of these analytes have been
shown previously to be stable under such conditions [36,
38]. All mobile phases were degassed for 25 min prior to
use. The following detection wavelengths were used: 308
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nm for R-warfarin and 255 nm for carbamazepine. The
void time of the system was determined by injecting a 25
μM sample of sodium nitrate that was prepared in the
mobile phase. The elution of sodium nitrate was monitored at 205 nm.
A 30 μM carbamazepine sample was chosen for this
work because no significant change was noted in the
measured retention of this analyte when over two-fold
higher or lower concentrations were used, thus indicating
that linear elution conditions were present for this sample. A 20 μM R-warfarin sample was utilized for similar
reasons. The central moment and second moment (i.e.,
moment 2, or the variance) were found for each peak by
using Peakfit 4.12 (Systat Software, San Jose, CA, USA)
along with the linear progressive baseline, Savitsky–Golay smoothing, and EMG peak fit settings of this software.
The central moment was used to determine the retention factor, and the second moment was used to measure
band-broadening and to calculate plate heights. The void
time of the system, as required for retention factor measurements, was determined by injecting 25 μM sodium
nitrate. Similar injections were made with no column
present in the system to correct for the extra-column void
time of the system and extra-column band-broadening.

3 Results and discussion
3.1 Retention of carbamazepine on HSA microcolumns
using silica monoliths
Zonal elution measurements of drug retention are often
made on HPLC affinity columns to estimate the percentage binding of a drug to an immobilized protein such as
HSA [41]. This approach is also used to examine the effect of a competing drug or solute on the binding by a site
selective probe to the column [34, 41, 47] and to examine
the effect of temperature or mobile phase composition on
drug–protein interactions [39, 41]. The use of zonal elution conditions in these experiments is applicable to the
study of solute–ligand systems with weak-to-moderate
strength interactions (i.e., as association equilibrium constant of 106 M–1 or lower) and relatively fast association/
dissociation kinetics; these conditions make this approach
an example of “weak affinity chromatography” (see references [39–41, 43] for more details). Carbamazepine is one
drug that has been used as a probe for Sudlow site II in
binding studies conducted on HSA columns [36]. Carbamazepine has an association equilibrium constant of 5.3
× 103 M–1 at pH 7.4 and 37°C with HSA [36]. This binding strength is typical of that seen for many drugs with
this protein [31, 42], making carbamazepine a good general model for the work that was conducted in this study.
This drug was used to see how varying both column size
and flow rate would affect binding studies that might be
made on affinity microcolumns.
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Figure 3. Chromatograms obtained for injections of 30 μM carbamazepine at 0.5 mL/min onto 4.6 mm i.d. HSA silica monoliths with lengths (from bottom-to-top) of 1, 3, or 5 mm. The
experimental conditions are given in the text.

Figure 3 shows chromatograms that were obtained at
0.5 mL/min for injections of carbamazepine on 4.6 mm
i.d. HSA microcolumns of various lengths made from
silica monoliths. The retention times noted for carbamazepine were 33, 49, and 64 s on the 1, 3, and 5 mm long
microcolumns, respectively. These retention times are
significantly shorter than the retention time of 10.6 min
that would be expected for carbamazepine at 0.5 mL/min
on a 10 cm × 4.6 mm i.d. HPLC silica monolith containing
HSA, based on data given in reference [23].
The back pressures measured for the 3 mm long HSA
affinity microcolumn made from a silica monolith ranged
from 256 psi (1.8 MPa) at 0.5 mL/min to 825 psi (5.7 MPa)
at 4.0 mL/min, with almost two-fold lower back pressures being recorded on the 1 mm long microcolumn. In
comparison, a 4.6 mm i.d. × 5 cm HSA column based on
silica particles has been reported to give a back pressure
of 995 psi (6.9 MPa) at 3.0 mL/min [23]. The relatively
low back pressures of the silica monoliths and higher
flow rates that could be employed with these columns
made it possible to further reduce the time needed for the
elution of drugs from these columns. In this case, a flow
rate of 4.0 mL/min gave retention times of 5.6– 8.3 s for
carbamazepine on the 1 to 5 mm long affinity microcolumns. These values are 50-fold lower than the typical retention time that would be expected for this drug at 0.5
mL/min on a 10 cm × 4.6 mm i.d. HSA column containing a silica monolith [23].
Figure 4 shows how the retention factor for carbamazepine changed with flow rate on the 1 and 5 mm × 4.6
mm i.d. HSA microcolumns containing a silica monolith. Similar results were obtained on the 3 mm × 4.6 mm
i.d. HSA microcolumn. It is desirable in zonal studies of
drug–protein binding to have a retention factor that does
not vary significantly with flow rate. Under these conditions, the mean position of the peak is typically assumed

Figure 4. Retention factors measured at various flow rates for
injections of 30 μM carbamazepine onto 4.6 mm i.d. HSA silica monoliths with lengths of (a) 5 mm or (b) 1 mm. The experimental conditions are given in the text. The error bars represent a range of ±1 S.D.

to represent a local equilibrium between the drug and
the immobilized protein. This assumption makes it possible to estimate the extent of drug–protein binding or to
study the equilibrium processes involved in this binding
by using the measured retention factor. It was found in
this report that similar retention factors were obtained
for carbamazepine even when going from the 5 mm ×
4.6 mm i.d. HSA microcolumn to the 1 mm × 4.6 mm
i.d. HSA microcolumn. For instance, the average retention factors measured at flow rates of 0.25–2.0 mL/min
on the 5 mm versus 1 mm long columns were 1.7 (±0.1)
and 2.4 (±0.2), respectively, while the average retention
factors determined at 0.25–6.0 mL/min were 2.1 (±0.5)
and 2.5 (±0.4). Comparable results were seen with the 3
mm long microcolumn. Small batch-to-batch differences
in protein coverage did lead to some corresponding column-to-column variations in the retention factors, such
as those at lower flow rates for the 1 and 5 mm column
results. However, the results in Figure 4 do clearly indicate that microcolumns in this size range could be used
in retention factor measurement for drug–protein binding studies.
The use of smaller microcolumns has the obvious advantage of allowing faster analysis times by providing
shorter column residence times and lower column backpressures. One disadvantage noted in Figure 4 in the
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use of very short microcolumns for drug-binding studies is that there is a loss in precision during retention factor measurements as the column length is decreased. The
5 mm long HSA microcolumns gave a precision in these
measurements between 0.25 and 6.0 mL/min that ranged
from ±0.5 to ±4% (average, ±2.6%), while the precision for
the 3 mm column under the same conditions was ±3 to
±16% (average, ±8%). In comparison, the 1 mm column at
these same flow rates had a precision of ±7 to ±33% (average, ±21%) for the measured retention factors of carbamazepine. This decrease in precision was related to the
faster elution times of carbamazepine from the shorter
microcolumns, which lowered the degree of certainty associated with the central moments determined for the
corresponding peaks.
Besides providing shorter analysis times, affinity microcolumns also require a smaller amount of immobilized
protein or ligand than traditional HPLC affinity columns.
For instance, the protein content of a 3.5 cm × 2.1 mm i.d.
HSA silica particle-based affinity column (i.e., one of the
smaller columns used in previous studies) has been reported to be 36 nmol HSA [47]. The 1 and 3 mm × 4.6 mm
i.d. affinity microcolumns used in this current report contained approximately 1.2 to 3.5 nmol HSA, or 10–30 fold
less protein than the column in reference [47]. These microcolumns also contained roughly 33–100-fold less protein than a 10 cm × 4.6 mm i.d. HPLC silica monolith that
was used in a previous study for the immobilization of
HSA [23].
One possible disadvantage of having lower protein
content in an affinity column is that smaller amounts
of sample must be injected to avoid column overloading and concentration-dependent changes in retention
(i.e., nonlinear elution effects). It was found in this report that samples containing up to 80 μM carbamazepine gave less than a 1.9–5.1% change in the measured
retention factor. This result indicated that such nonlinear effects were not a significant problem at the typical
concentration of 30 μM carbamazepine that was used
throughout this study for all of the affinity microcolumns (similar results were obtained for R-warfarin later
in this report).
3.2 Band-broadening of carbamazepine on HSA microcolumns using silica monoliths
The band-broadening and width of peaks obtained in
zonal elution studies with affinity columns are also of interest because this information can be used to learn about
the kinetics of drug–protein binding [41, 42]. This technique again works well for solute –ligand systems with
weak-to-moderate strength interactions and relatively
fast association/dissociation kinetics, such as those that
occur between many drugs and small solutes with HSA
[41, 43]. This type of experiment requires the ability to
measure plate heights over a wide range of flow rates.
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Figure 5. Plate height plots obtained for injections of 30 μM carbamazepine onto 4.6 mm i.d. HSA silica monoliths with lengths
of (a) 5 mm or (b) 1 mm. The experimental conditions are given
in the text. The error bars represent a range of ±1 S.D.

The next series of studies in this report examined the possible use of affinity microcolumns and silica monoliths for
such work.
Figure 5 shows some typical plate height plots that
were generated using the 1 and 5 mm long HSA microcolumns. Comparable plots were obtained for the 3 mm long
column. The plate heights measured for these columns
were all between 0.5 and 0.8 mm at 37°C and showed no
appreciable change over the linear velocities that were
examined in this report. These values are comparable to
plate heights of 0.4–0.7 mm that have been reported at
25°C on a 10 cm × 4.6 mm i.d. HSA silica monolith using l-tryptophan as the analyte (i.e., a solute that binds
to Sudlow site II with a similar strength to that of carbamazepine) [23]. The little or no change seen in the plate
height over the linear velocities that were tested in this report indicates that these conditions were obtained over
the region in which contributions from stationary phase
mass transfer and stagnant mobile phase mass transfer
dominate the plot in Figure 5.
The corresponding number of theoretical plates for
carbamazepine on the HSA microcolumns was approximately 1–2, 3–6, or 8–9 for the 1, 3, and 5 mm long columns, respectively. Given the small number of theoretical plates that were present on the 1 mm long column,
it was somewhat surprising to see that the measured
plate heights for this column gave such good agreement
with the values for the longer 3 and 5 mm HSA columns
in this report, as well as with data for a 10 cm HSA sil-
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ica monolith that has been used in previous studies [23].
This may reflect the presence of relatively fast association
and dissociation kinetics for carbamazepine with immobilized HSA, as has been previously observed for l-tryptophan [48].
One disadvantage of using affinity microcolumns
to determine plate heights is that there was a clear decrease in the precision of these measurements as the column length was decreased, especially when going from
the 5 mm column to the 1 mm long column. For the 5 mm
long column, the precision of the plate heights in Figure
5 ranged from ±1.2 to ±15%, with an average precision of
±7%. The 3 mm long column gave similar precision values, which ranged from ±.4 to ±%, with an average precision of ±5%. In comparison to these results, the 1 mm
long column gave precision that varied between ±3 to
±29%, with an average precision of ±10%. Although high
precision plate height measurements may require longer columns [41–43], these data do suggest that affinity microcolumns can be used to provide good estimates
of plate heights for at least the preliminary screening of
drug–protein interaction kinetics while also minimizing
the amount of time required for such studies.
3.3 Retention of warfarin on HSA microcolumns using
silica monoliths
Warfarin is frequently used in zonal elution studies
as a probe for Sudlow site I in drug competition studies on HSA columns [34, 47]. The binding of warfarin
with HSA columns has been previously characterized in
terms of both the equilibrium constant [39] and rate constants [40] for this interaction. One challenge in working with warfarin is its strong binding for HSA. For instance, the association equilibrium constant of an HSA
column for R-warfarin has been found to be 2.1 × 105
M–1 at pH 7.4 and 37°C, with S-warfarin having slightly
stronger binding under these conditions [38, 40]. Many
previous studies using HSA in HPLC columns have employed columns with lengths of 4–10 cm, which give relatively long retention times for warfarin (e.g., 25–150
min) due to the strong binding of this drug to these columns [23, 34, 38, 47]. The use of an affinity microcolumn
is particularly attractive for this drug because it could
significantly reduce the time required in experiments
that use either R- or S-warfarin as site selective probes
for HSA when examining the binding of new drug candidates to this protein [34].
Some typical chromatograms are shown in Figure 6 for
injections of R-warfarin onto a 3 mm × 4.6 mm i.d. HSA
microcolumn containing a silica monolith. The retention
times noted for R-warfarin on this microcolumn were 5.4
min at 1.0 mL/min and 9.5 min at 0.5 mL/min. These retention times are shorter than the 150–160 min retention time that was observed earlier for R-warfarin at 1.0
mL/min on a 10 cm × 4.6 mm i.d. HPLC silica monolith
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Figure 6. Chromatograms obtained at various flow rates for
injections of 20 μM R-warfarin on a 3 mm × 4.6 mm i.d. HSA
silica monolith column. The experimental conditions are given
in the text.

containing HSA [23]. These retention times are also lower
than values of 12–15 min or 20–25 min, respectively, that
have been obtained at 0.5 mL/min for 5 cm × 4.1 mm i.d.
or 10 cm × 4.1 mm i.d. HSA columns using silica particles [38, 49]. Similar results would be expected for S-warfarin, which typically has a retention factor that is slightly
higher than for R-warfarin under the mobile phase and
temperature conditions used in this study [39]. Racemic warfarin was not used in this current report because
it was expected from previous results with larger HSA
columns that the affinity microcolumns would not have
sufficient resolution to separate R- and S-warfarin, thus
complicating the determination of retention and bandbroadening for such analytes if a racemic mixture was
used as the sample [23, 39].
The relatively low back-pressures and high flow rates
that could be used with silica monoliths made it possible to further reduce the time needed for the elution of Rwarfarin. In this case, a flow rate of 4.0 mL/min on the affinity microcolumn gave a retention time of 1.37 min for
R-warfarin, which was at least ten-fold lower than the
typical retention times noted at 0.5 mL/min on 4.1 mm
i.d. × 4.5 cm HSA columns containing silica particles [49]
and over 100-fold lower than the retention time seen at
1.0 mL/min on a 10 cm × 4.6 mm i.d. HPLC silica monolith containing HSA [23].
Figure 7a shows how the retention factor for R-warfarin changed with flow rate on the 3 mm × 4.6 mm i.d.
HSA microcolumn containing a silica monolith. This retention factor had an average value of 65 (±7) in going
from 0.5 to 4.0 mL/min, with a variation of only 7% being noted at flow rates ranging from 1 to 4 mL/min. The
precision of retention factors measured at the individual
flow rates in this range varied from ±0.9 to ±4.0%, with
an average of ±2%. These results again indicated that an
affinity microcolumn of this size and containing a silica
monolith could be used to provide reproducible retention
factors for drug–protein binding studies. It is interesting
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Figure 8. Plate height plots obtained for injections of 20 μM R
-warfarin on a 3 mm × 4.6 mm i.d. HSA silica monolith or a 3
mm × 2.1 mm i.d. HSA column containing silica particles. The
experimental conditions are given in the text. The error bars
represent a range of ±1 S.D.

Figure 7. Retention factors obtained at various flow rates for
injections of 20 μM R-warfarin obtained on (a) a 3 mm × 4.6
mm i.d. HSA silica monolith column and (b) a 3 mm × 2.1 mm
HSA column containing silica particles. The experimental conditions are given in the text. The error bars represent a range
of ±1 S.D.

to note that the precision seen for the retention factors
of R-warfarin on the 3 mm × 4.6 mm i.d. HSA microcolumn was much better than that obtained earlier for carbamazepine on the same column. This difference occurred
because of the much higher retention of R-warfarin versus carbamazepine, which made it easier to measure the
retention factor for the former analyte. The same general
trend would be expected on other affinity microcolumns
when comparing drugs that have strong binding to an
immobilized protein versus those with weak-to-moderate
binding.
3.4 Band-broadening of warfarin on HSA microcolumns
made with silica monoliths
The band-broadening of warfarin on the HSA microcolumns was next examined. This topic was of interest
because measurements of band-broadening have been
previously employed to examine the kinetics of R-warfarin association and dissociation on traditional HPLC affinity columns containing HSA [40].
Figure 8 shows a plate height plot obtained on the 3
mm × 4.6 mm i.d. HSA microcolumn containing a silica monolith. This plate height plot was fairly flat, with
a variation of only ±12% being seen in the measured
plate heights between linear velocities of 0.01 and 0.05

cm/s (i.e., flow rates of 0.5 to 4.0 mL/min). Similar plate
height plots have been observed at linear velocities
spanning from roughly 0.12 to 0.35 cm/s for the injection of racemic warfarin on a 10 cm × 4.6 mm i.d. HPLC
silica monolith containing HSA [23]. The small change
noted in the plate height with linear velocity in Figure
8 indicates that these conditions were obtained over the
region in which contributions from stationary phase
mass transfer and stagnant mobile phase mass transfer
dominate.
The plate heights measured here, which were around
0.2 mm at 37°C, were slightly higher than values of 0.04–
0.06 mm that have been reported at 25°C for R-warfarin
on the 10 cm × 4.6 mm i.d. HSA silica monolith used in
reference [23]. The corresponding number of theoretical plates for R-warfarin on the 3 mm × 4.6 mm i.d. HSA
silica monolith was 11.5 to 15.2 at the given flow rates.
The precision of the plate heights found using the affinity microcolumns ranged from ±5 to ±20%, with an average precision of ±11%. This level of precision was actually slightly lower than noted earlier for carbamazepine
but was sufficient for at least the preliminary screening of
drug–protein interactions when using this type of affinity
microcolumn.
3.5 HSA affinity microcolumns using silica monoliths
versus silica particles
The final section of this study involved a comparison between affinity microcolumns that contained silica monoliths and similar affinity microcolumns that contained 7
μm silica particles. R-Warfarin was used as the model analyte in this comparison and an intermediate microcolumn length of 3 mm was employed for this work. The
same preparation of HSA and the same immobilization
method (i.e., the Schiff base technique) were used for
all supports in this investigation. It has been noted earlier that HSA silica monoliths can be prepared with up
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to a third more protein per unit volume than can be obtained with silica particles [23]. In this current study, a silica monolith with only a slightly higher content than the
silica particles was used in preparing the HSA columns.
The HSA content in the silica monolith was estimated to
be 0.36 (±0.02) μmol/mL and the content in the column
with silica particles was 0.34 (±0.02) μmol/ mL. As shown
in Figure 7, the use of the same protein, immobilization
method, and similar protein contents resulted in similar
retention factors for R-warfarin on these columns, with an
average retention factor that was 16% higher for the silica
monolith.
Like the results noted earlier in Figure 7a for the HSA
silica monoliths, the retention factors given in Figure 7b
for R-warfarin on the HSA microcolumn packed with 7
μm silica particles gave consistent results up to flow rates
of 4.0 mL/min. The variation in the results in Figure 7b
was ±7% between 0.1 and 4.0 mL/min, which was the
same variation found in Figure 7a for data obtained using
the HSA silica monolith. The precision of the retention
factors measured on the column containing silica particles ranged from ±1.8 to ±14%, with an average of ±6%.
This precision was slightly worse than noted for the HSA
microcolumn based on a silica monolith, but indicated
that the silica particle-based microcolumn could also be
used to provide reasonably reproducible retention factors
for drug–protein binding experiments.
A larger difference between the microcolumns using
a silica monolith or silica particles was seen when comparing their efficiencies (see Figure 8). Although the silica monolith gave consistent plate heights throughout the
range of linear velocities that were sampled, the column
containing silica particles gave a consistent increase in
plate with linear velocity over the same range. These results agree with plate height plots that have been previously reported for R-warfarin on a 10 cm × 4.6 mm i.d.
HSA silica monolith and an HSA column of a comparable
size containing silica particles [23]. At the highest linear
velocities that were used, the silica monolith gave plate
heights that were almost five-fold lower than those for
the HSA microcolumn with 7 μm silica particles (note: a
smaller difference would be expected when using particles with a diameter of 3 or 5 μm). This difference gave
the silica monolith a greater number of theoretical plates
and greater efficiency at higher flow rates. This property,
in turn, should make it easier to use affinity microcolumns based on silica monoliths at these higher flow rates
for the rapid screening or characterization of drug–protein binding.

4 Conclusions
This report examined the development and use of affinity microcolumns containing HSA silica monoliths for
the high-throughput analysis of drug–protein interac-
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tions. Studies using carbamazepine or warfarin as the injected analyte indicated that microcolumns as short as 1
to 3 mm could be used to provide reproducible estimates
of retention factors or plate heights. Some benefits that
were noted when using smaller columns for these measurements included the lower retention times and lower
back pressures that could be obtained versus traditional
HPLC affinity columns. Another benefit was the smaller
amount of protein that was required for column preparation. One disadvantage with decreasing column length
was the lower precision that resulted in retention factor
and plate height measurements. Another possible disadvantage that was not a problem in this particular study
was the lower sample capacity of the shorter columns.
A comparison was also made between HSA microcolumns containing 7 μm silica particles versus silica monoliths. It was found in work with R-warfarin that both
types of supports could be used in HSA microcolumns
for the determination of retention factors or plate heights
in drug–protein binding studies. However, the better efficiency of the silica monolith made this the preferred support for work in which higher flow rates or a larger number of theoretical plates are needed for the analysis of
drug–protein interactions. The information provided in
this report should be useful in creating and adapting affinity microcolumns that contain HSA or other proteins
for drug–binding studies. The ability of these microcolumns to provide reproducible results in a short amount
of time should be particularly appealing for the highthroughput screening of drug–protein binding or in the
rapid determination of percentage binding, binding affinity, or dissociation/association rates for proteins with
drug candidates [41–43].
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